This article is more than 5 years old. Information may no longer be current.
Half-fluence PDT improves acute symptomatic central serous chorioretinopathy
Click Here to Manage Email Alerts
Half-fluence photodynamic therapy and verteporfin guided with indocyanine green angiography treated acute symptomatic central serous chorioretinopathy, according to a study.
The retrospective study included 19 eyes of 19 phakic patients with subfoveal fluid resulting from acute symptomatic central serous chorioretinopathy identified via spectral-domain optical coherence tomography and fluorescein angiography. Mean patient age was 45.9 years.
At baseline, mean ETDRS best corrected visual acuity was 47 letters, mean spherical equivalent refractive error was 0.16 D, and mean central foveal thickness was 406 µm.
Patients underwent indocyanine green angiography-guided PDT at half-fluence (25 J/cm2) with verteporfin (6 mg/m2).
Acute symptomatic central serous chorioretinopathy was defined as a first episode of symptoms persisting less than 12 weeks before treatment; symptoms lasted a mean 31.7 days before treatment.
Investigators evaluated patients before treatment and at 1, 3, 6, 9 and 12 months after treatment.
At 12 months after treatment, mean BCVA was 56 letters; the improvement was statistically significant (P = .003). Mean central foveal thickness was 243 µm; the reduction was statistically significant (P < .001).
Subretinal fluid was fully resolved in all 19 eyes at 1 month after treatment, and there was no recurrence of symptoms or side effects at 12 months.
Click Here to Manage Email Alerts